175 related articles for article (PubMed ID: 38328802)
21. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
22. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.
Mosbech H; Canonica GW; Backer V; de Blay F; Klimek L; Broge L; Ljørring C
Ann Allergy Asthma Immunol; 2015 Feb; 114(2):134-40. PubMed ID: 25624131
[TBL] [Abstract][Full Text] [Related]
23. Morning Versus Evening Dosing of Sublingual Immunotherapy in Allergic Asthma: A Prospective Study.
Liao F; Chen S; Wang L; Quan YY; Chen LL; Lin GH
Front Pediatr; 2022; 10():892572. PubMed ID: 35757136
[TBL] [Abstract][Full Text] [Related]
24. New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases.
Ferrando M; Bagnasco D; Passa-Lacqua G; Puggioni F; Varricchi G; Canonica GW
Curr Pharm Biotechnol; 2017; 18(5):378-383. PubMed ID: 28413977
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
[TBL] [Abstract][Full Text] [Related]
26. New perspectives in allergen specific immunotherapy driven by big trials with house dust mite sublingual SQ
Vitiello G; Maltagliati L; Rossi O
Clin Mol Allergy; 2020; 18():10. PubMed ID: 32536827
[TBL] [Abstract][Full Text] [Related]
27. The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease.
Emminger W; Hernández MD; Cardona V; Smeenk F; Fogh BS; Calderon MA; de Blay F; Backer V
Int Arch Allergy Immunol; 2017; 174(1):35-44. PubMed ID: 28950268
[TBL] [Abstract][Full Text] [Related]
28. Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens.
Trebuchon F; Lhéritier-Barrand M; David M; Demoly P
Clin Transl Allergy; 2014; 4():15. PubMed ID: 24910771
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of house dust mite sublingual immunotherapy tablets in allergic rhinitis: A systematic review and meta-analysis.
Kulalert P; Phinyo P; Lao-Araya M
World Allergy Organ J; 2022 Sep; 15(9):100691. PubMed ID: 36119654
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma.
Canonica GW; Virchow JC; Zieglmayer P; Ljørring C; Smith IM; Mosbech H
Expert Rev Clin Immunol; 2016 Aug; 12(8):805-15. PubMed ID: 27322777
[TBL] [Abstract][Full Text] [Related]
31. SQ house dust mite sublingual immunotherapy for the treatment of adults with house dust mite-induced allergic rhinitis.
Meteran H; Backer V
Expert Rev Clin Immunol; 2019 Nov; 15(11):1127-1133. PubMed ID: 31584839
[No Abstract] [Full Text] [Related]
32. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study.
Bahçeciler NN; Işik U; Barlan IB; Başaran MM
Pediatr Pulmonol; 2001 Jul; 32(1):49-55. PubMed ID: 11416876
[TBL] [Abstract][Full Text] [Related]
33. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma.
Eifan AO; Calderon MA; Durham SR
Expert Opin Biol Ther; 2013 Nov; 13(11):1543-56. PubMed ID: 24099116
[TBL] [Abstract][Full Text] [Related]
34. Comparison of rush-subcutaneous and sublingual immunotherapy with house dust mite extract for pediatric allergic rhinitis: A prospective cohort study.
Hamada M; Saeki K; Tanaka I
Allergol Int; 2023 Oct; 72(4):573-579. PubMed ID: 36918306
[TBL] [Abstract][Full Text] [Related]
35. Methods for Experimental Allergen Immunotherapy: Subcutaneous and Sublingual Desensitization in Mouse Models of Allergic Asthma.
Hesse L; Petersen AH; Nawijn MC
Methods Mol Biol; 2021; 2223():295-335. PubMed ID: 33226602
[TBL] [Abstract][Full Text] [Related]
36. The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis.
Zhao L; Zhang Y; Zhang S; Zhang L; Lan F
Expert Rev Clin Immunol; 2021 Sep; 17(9):969-975. PubMed ID: 34388949
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of sublingual immunotherapy for house dust mite allergic rhinitis.
Cingi C; Bayar Muluk N; Ulusoy S; Acar M; Şirin S; Çobanoğlu B; Birdane L; Kalaycık Ç; Çakır BÖ; Oğhan F; Aynacı S; Erdoğmuş N; Yıldırım Ö; Şahin E; Bulut F; Aksoy MA; Türe N; Bal C
Eur Arch Otorhinolaryngol; 2015 Nov; 272(11):3341-6. PubMed ID: 25516223
[TBL] [Abstract][Full Text] [Related]
38. Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma.
Hesse L; Nawijn MC
Methods Mol Biol; 2017; 1559():137-168. PubMed ID: 28063043
[TBL] [Abstract][Full Text] [Related]
39. Circulating T follicular helper 2 cells, T follicular regulatory cells and regulatory B cells are effective biomarkers for predicting the response to house dust mite sublingual immunotherapy in patients with allergic respiratory diseases.
Shigehara K; Kamekura R; Ikegami I; Sakamoto H; Yanagi M; Kamiya S; Kodama K; Asai Y; Miyajima S; Nishikiori H; Uno E; Yamamoto K; Takano K; Chiba H; Ohnishi H; Ichimiya S
Front Immunol; 2023; 14():1284205. PubMed ID: 38111589
[TBL] [Abstract][Full Text] [Related]
40. [The efficacy of sublingual specific immunotherapy in children with allergic rhinitis].
Li P; Fa M; Huang ZH; Xie LS; Xu Y; Chen WB; Zhang JY; Zhang XR; Zhu Z; Li Q
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Apr; 30(7):546-551. PubMed ID: 29871066
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
